Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/ueg2.12103 http://scihub22266oqcxt.onion/10.1002/ueg2.12103 34102015!8242672!34102015     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       United+European+Gastroenterol+J 2021 ; 9 (7): 787-796 Nephropedia Template TP {{tp|p=34102015|t=2021. What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective |pdf=|usr=}}{{34102015}} gab.com Text What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective JO: United European Gastroenterol J http://www.kidney.de/pget.php?&tw=1&pmid=34102015 #FOAvip BACKGROUND: The novel Coronavirus (SARS-CoV-2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID-19 vaccines, and a few more are going to be approved soon. METHODS: Several different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non-replicating viral vector vaccines, RNA based vaccines, DNA based vaccines). RESULTS: Since vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS-CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients. CONCLUSIONS: Thus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID-19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination. Twit Text FOAVip What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective ????United European Gastroenterol J http://www.kidney.de/pget.php?&tw=1&pmid=34102015 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34102015 #FOAvip English Wikipedia <ref>{{Cite pmid|34102015}}</ref> What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective #MMPMID34102015 Spadaccini M; Canziani L; Aghemo A; Lleo A; Maselli R; Anderloni A; Carrara S; Fugazza A; Pellegatta G; Galtieri PA; Hassan C; Greenwald D; Pochapin M; Wallace M; Sharma P; Roesch T; Bhandari P; Emura F; Raju GS; Repici A United European Gastroenterol J 2021[Sep]; 9 (7): 787-796 PMID34102015show ga BACKGROUND: The novel Coronavirus (SARS-CoV-2) has caused almost 2 million deaths worldwide. Both Food and Drug Administration and European Medicines Agency have recently approved the first COVID-19 vaccines, and a few more are going to be approved soon. METHODS: Several different approaches have been used to stimulate the immune system in mounting a humoral response. As more traditional approaches are under investigation (inactivated virus vaccines, protein subunit vaccines, recombinant virus vaccines), more recent and innovative strategies have been tried (non-replicating viral vector vaccines, RNA based vaccines, DNA based vaccines). RESULTS: Since vaccinations campaigns started in December 2020 in both the US and Europe, gastroenterologists will be one of the main sources of information regarding SARS-CoV 2 vaccination for patients in their practice, including vulnerable patients such as those with Inflammatory Bowel Disease (IBD), patients with chronic liver disease, and GI cancer patients. CONCLUSIONS: Thus, we must ourselves be well educated and updated in order to provide unambiguous counseling to these categories of vulnerable patients. In this commentary, we aim to provide a comprehensive review of both approved COVID-19 vaccines and the ones still under development, and explore potential risks, benefits and prioritization of vaccination. |2019-nCoV Vaccine mRNA-1273[MESH] |Ad26COVS1/therapeutic use[MESH] |BNT162 Vaccine/therapeutic use[MESH] |COVID-19 Vaccines/*therapeutic use[MESH] |COVID-19/*prevention & control[MESH] |ChAdOx1 nCoV-19/therapeutic use[MESH] |Gastroenterology[MESH] |Gastrointestinal Neoplasms/therapy[MESH] |Humans[MESH] |Inflammatory Bowel Diseases/therapy[MESH] |Liver Diseases/therapy[MESH]What gastroenterologists should know about SARS-CoV 2 vaccine: World E(epmc).pdf DeepDyve Pubget Overpricing